Inhibition of lung inflammatory reactions in rats by an anti-human IL-8 antibody.
IL-8 belongs to the family of chemotactic cytokines and may play an important role in the inflammatory response. In the current studies, a murine mAb (DM/C7) to human rIL-8 was found to have protective effects in inflammatory lung injury in rats. DM/C7 was nonreactive with the rat cytokine-induced neutrophil chemoattractant peptide. In vivo, DM/C7 blocked the glycogen-induced accumulation of neutrophils in rats and was highly protective against lung and dermal vascular injury after deposition of IgG immune complexes. The latter model of injury has recently been shown to be E-selectin dependent. The protective effects of DM/C7 correlated with reduced tissue accumulation of neutrophils, as measured by myeloperoxidase content. DM/C7 reacted with an epitope expressed by TNF-alpha-stimulated rat pulmonary artery endothelial cells and with the pulmonary vascular endothelium after intrapulmonary deposition of IgG immune complexes. In the model of IgG immune complex-induced lung injury, the protective effects of DM/C7 were abolished by prior absorption of the antibody with human rIL-8. Polyclonal antibody to cytokine-induced neutrophil chemoattractant peptide failed to protect against IgG immune complex-induced vascular injury even though this antibody blocked the in vitro chemotactic activity of cytokine-induced neutrophil chemoattractant. In the model of rapidly developing lung injury due to systemic activation of C after infusion of cobra venom factor, DM/C7 was not protective. As well, in the neutrophil-independent model of IgA immune complex-induced lung injury, treatment with DM/C7 was not protective. These data indicate that in inflammatory lung injury that is linked to E-selectin-dependent recruitment of neutrophils in rats, antibody to human IL-8 also blocks recruitment of neutrophils and thereby affords protection against lung injury. The data suggest the presence of an IL-8-like product in this model of lung injury.
Mulligan
M S
MS
Department of Pathology, University of Michigan Medical School, Ann Arbor 48109-0602.
Jones
M L
ML
Bolanowski
M A
MA
Baganoff
M P
MP
Deppeler
C L
CL
Meyers
D M
DM
Ryan
U S
US
Ward
P A
PA
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D000936:Antigen-Antibody Complex / Q000276:immunology; D004546:Elapid Venoms / Q000633:toxicity; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007150:Immunohistochemistry; D016209:Interleukin-8 / Q000032:analysis / Q000276:immunology / Q000502:physiology*; D008168:Lung / Q000737:chemistry / Q000473:pathology; D008297:Male; D009195:Peroxidase / Q000032:analysis; D011014:Pneumonia / Q000517:prevention & control*; D011651:Pulmonary Artery / Q000737:chemistry; D051381:Rats; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
D000911:Antibodies, Monoclonal; D000936:Antigen-Antibody Complex; D004546:Elapid Venoms; D007074:Immunoglobulin G; D016209:Interleukin-8; D014409:Tumor Necrosis Factor-alpha; C016310:cobra venom factor; D009195:Peroxidase